Parlodel
(Bromocriptine)ApprovedSmall molecule
Bromocriptine is used to treat high prolactin levels (a hormone) in the body, which can cause fertility problems and irregular periods, and it's also used to treat Parkinson's disease symptoms.[2] Parlodel is currently approved and in use across 9 indications[4].[1]
Parlodel is one of 194 small molecule programs targeting Primary Aldosteronism. It is currently in Approved.
9
Indications
23
Total Trials
2
Active Trials
193
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
13
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
177 competitors in Obesity
#DrugCompanyPhaseTrials
1Parlodel
VVeroScience
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Berobenatide
PfizerPhase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Cagrisema
Novo NordiskPhase 3
Eloralintide
Eli LillyPhase 3
Naltrexone-Bupropion Combination
CCurrax Pharmaceuticals
Phase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Parkinson's Disease3 trials
Ovarian Hyperstimulation Syndrome2 trials
Peripartum Cardiomyopathy2 trials
Treatment1 trial
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
Terminated·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·N/A·NCT01893450·31 enrolled
Function1 trial
14 more indications
Insulin resistance1 trial
ISS1 trial
Dopaminergic Effects on Brown Adipose Tissue
Completed·—·N/A·NCT02428933·8 enrolled
Insulin Sensitivity1 trial
Bromocriptine and Insulin Sensitivity
Completed·—·N/A·NCT02428946·15 enrolled
Satisfaction1 trial
Satisfaction of Patients With the Chosen Method of Inhibition of Lactation
Unknown status·—·N/A·NCT04038749·90 enrolled
Primary Aldosteronism1 trial
Phase II1 trial
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
Suspended·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00004300·40 enrolled
Anorexia Nervosa1 trial
Regulatory
FDA Approval Timeline[5]
Mar 1, 1982
PARLODEL
NDA NDA017962
May 5, 2009
CYCLOSET
NDA NDA020866
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Parlodel drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Bromocriptine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- D2-Like Dopamine Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- VVeroScience